ALLMedicine™ Narcolepsy Center

May 2nd, 2021 - Polysomnographic studies have been conducted to explore nighttime sleep features in narcolepsy, but their relationship to narcolepsy is still imperfectly understood. We conducted a systematic review of the literature exploring polysomnographic dif...

Apr 22nd, 2021 - To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). PubMed (1966 to January 2021) was searched using the terms solriam...

Apr 22nd, 2021 - How treatable is narcolepsy with current pharmacotherapy and what does the future hold?|2021|Pellitteri G,de Biase S,Valente M,Gigli GL,|

Apr 22nd, 2021 - High-Dose Intravenous Methylprednisolone May Have Long-Term Benefits on the Daytime Sleepiness of Narcolepsy: A Case Report.|2021|Hsu KC,Malik M,Shen JY,Tsai MC,Tsai CK,|

Apr 22nd, 2021 - Narcolepsy is a rare, chronic, and disabling central nervous system hypersomnia; two forms can be recognized: narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Its etiology is still largely unknown, but studies have reported a strong associatio...

Mar 19th, 2019 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstr...

Nov 30th, 2010 - Assessment for sleep disorders in children has long relied on a comprehensive history and physical exam. In certain conditions, most commonly sleep related breathing disorders (SRBD), polysomnography (PSG) was performed as an adjunctive tool to ai.

May 28th, 2009 - We reviewed the literature for disease-specific markers in cerebrospinal fluid (CSF) and evaluated their diagnostic and prognostic relevance in neurological diseases. High tau protein in combination with low amyloid beta levels has a high sensitiv...

Feb 5th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...

WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy

May 2nd, 2021 - Polysomnographic studies have been conducted to explore nighttime sleep features in narcolepsy, but their relationship to narcolepsy is still imperfectly understood. We conducted a systematic review of the literature exploring polysomnographic dif...

Apr 29th, 2021 - A novel, once-nightly formulation of sodium oxybate is safe and effective for treating both subjective and objective symptoms of narcolepsy, new research suggests. Top-line results from the phase 3 REST-ON trial released earlier this year showed t...

Apr 22nd, 2021 - To review efficacy, safety, and place in therapy of solriamfetol for management of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). PubMed (1966 to January 2021) was searched using the terms solriam...

Apr 22nd, 2021 - How treatable is narcolepsy with current pharmacotherapy and what does the future hold?|2021|Pellitteri G,de Biase S,Valente M,Gigli GL,|

Apr 22nd, 2021 - High-Dose Intravenous Methylprednisolone May Have Long-Term Benefits on the Daytime Sleepiness of Narcolepsy: A Case Report.|2021|Hsu KC,Malik M,Shen JY,Tsai MC,Tsai CK,|

Apr 29th, 2021 - A novel, once-nightly formulation of sodium oxybate is safe and effective for treating both subjective and objective symptoms of narcolepsy, new research suggests. Top-line results from the phase 3 REST-ON trial released earlier this year showed t...

Nov 18th, 2020 - The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update on the potential risk of congenital malformations with the use of the narcolepsy drug modafinil during pregnancy. The update follows a European review o...

Oct 8th, 2020 - Discussion This case is very challenging because the patient had the findings of and met the criteria for OSA, periodic limb movement disorder (PLMD)/restless legs syndrome (RLS), and hypersomnolence. She also had several historical findings that ...

Oct 6th, 2020 - NEW YORK (Reuters Health) - The selective norepinephrine-dopamine-reuptake inhibitor solriamfetol is well-tolerated and effective for treating excessive daytime sleepiness (EDS) in patients with narcolepsy or obstructive sleep apnea (OSA), accordi...

Aug 2nd, 2020 - Difficulty with sleep is common, with some studies showing as many as 1 in 3 individuals report some type of sleep disorder. Reduced sleep duration has been linked to almost half of the 15 leading causes of death in the United States. From poor pe...